CRISPR-Cas Sigma Enzyme With Single-Guide RNA and Simpler PAM Recognition

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current CRISPR/Cas systems have limitations such as requiring multiple RNAs, complex PAM sequences, and varying sizes, which affect their efficiency and specificity in gene editing.

Innovation Solution

Development of a new CRISPR/Cas system with a novel RNA-guided endonuclease having specific amino acid sequences and derivatives, capable of binding to guide RNA and cutting target sequences efficiently.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If a new CRISPR/Cas system is developed to improve transfection efficiency and PAM recognition, then delivery efficiency and editing capability are improved, but system complexity and development difficulty increase

Engineering Contradiction:
Improvegene editing efficiencyVSAvoidsystem complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The CRISPR system is divided into distinct functional modules: guide RNA molecules with specific sequences, Cas effector proteins with defined PAM recognition domains, and modular fusion protein constructs. This segmentation allows independent optimization of each component's function while maintaining overall system efficiency.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The developed Cas effector proteins are designed to recognize multiple PAM sequence variants (including 5'-TTN, 5'-ANT, 5'-ATN motifs), enabling a single system to target diverse genomic locations. Fusion proteins combine multiple functional domains to achieve both cleavage and anti-crisp functions simultaneously.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Manufacturing precision

If existing CRISPR/Cas systems are used, then PAM sequence complexity is reduced, but off-target effects increase and editing precision decreases

Engineering Contradiction:
Improvegene editing precisionVSAvoidoff-target effects
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The guide RNA molecules are designed with localized sequence features including specific 5'-end modifications and optimized spacer regions that enhance target specificity. The Cas effector proteins possess localized PAM recognition domains that precisely distinguish on-target from off-target sequences through localized molecular interactions.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

Guide RNA molecules serve as intermediaries between the Cas effector protein and the target DNA sequence, providing an additional layer of specificity through RNA-DNA hybridization. The guide RNA's sequence complementarity and structural features mediate precise target recognition while preventing off-target binding.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The new CRISPR/Cas system enhances gene editing efficiency and specificity by utilizing a single guide RNA and simplified PAM sequences, reducing off-target effects.

Implementation Method 1

specifically binding to target sequences on the genome through RNA guidance

Methodology Applied
Scientific EffectComplementary base pairing:

Implementation Method 2

cutting the DNA to produce double-strand breaks

Methodology Applied
Scientific EffectEndonuclease activity: Enzyme

Data Source

PatentUS12630847B2CRISPR-Cas sigma enzyme and system
Publication Date: 2026.05.19 CHINA AGRI UNIV
  • US12630847B2 patent drawing
  • US12630847B2 patent drawing

AI summary

The present invention relates to the field of nucleic acid editing, in particular to the field of clustered regularly interspaced short palindromic repeat (CRISPR) technology. Specifically, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The present invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing), which comprise the proteins or fusion proteins of the present invention, or nucleic acid molecules encoding them. The present invention also relates to a method for nucleic acid editing (e.g., gene or genome editing), which uses the proteins or fusion proteins comprising the present invention.